Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases

Curr Top Med Chem. 2023;23(28):2609-2620. doi: 10.2174/0115680266264515230921052521.

Abstract

Bruton tyrosine kinase (BTK) is an important protein of the tyrosine kinase family and plays a key role in signal transduction, proliferation, migration, and survival in B lymphocytes. The inhibition of BTK is a promising therapy for various autoimmune diseases (AD) involving abnormal B cell function, such as rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE). This article briefly summarizes the role of BTK in the BCR signaling pathway, the development process of BTK inhibitors, and especially the latest progress of their clinical trials for the treatment of AD.

Keywords: Autoimmune disease; B cell receptor; Bruton's tyrosine kinase; Inhibitors; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus..

MeSH terms

  • Arthritis, Rheumatoid* / drug therapy
  • Autoimmune Diseases* / metabolism
  • B-Lymphocytes
  • Humans
  • Protein Kinase Inhibitors / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases
  • Signal Transduction

Substances

  • Protein-Tyrosine Kinases
  • Protein Kinase Inhibitors